|
|
|
|
|
|
|
|
open access
"....It is interesting to note that the anti–PD-1 MoAb demonstrated clinical objective responses in patients with previously presumed “nonimmunogenic” tumor types, including non-small cell lung cancer (NSCLC) and ovarian cancer, in whom durable partial responses (PRs) and stable disease were observed.[10] ....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.